Holen Sie sich die Stockscreener-App
5.44
6.88%
0.35
Vorhandelsmarkt:
5.63
0.19
+3.49%
Schlusskurs vom Vortag:
$5.09
Offen:
$5.205
24-Stunden-Volumen:
5.41M
Relative Volume:
0.89
Marktkapitalisierung:
$1.66B
Einnahmen:
$79.21M
Nettoeinkommen (Verlust:
$-143.96M
KGV:
-11.34
EPS:
-0.4796
Netto-Cashflow:
$-189.60M
1W Leistung:
+6.88%
1M Leistung:
+33.01%
6M Leistung:
+62.39%
1J Leistung:
+74.36%
1-Tages-Spanne:
$5.17
$5.76
1-Wochen-Bereich:
$5.01
$5.76
52-Wochen-Spanne:
$2.745
$6.79
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
5.44 | 1.61B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
ABCL - Finviz
AbCellera Biologics shareholders approve director elections and auditor at annual meeting - Investing.com
Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions? - simplywall.st
AbCellera Biologics (ABCL) grants director 111,701 share options - Stock Titan
AbCellera (ABCL) director Stephen Quake awarded 111,701 share options - Stock Titan
AbCellera (ABCL) director receives 111,701 share options grant - Stock Titan
AbCellera (NASDAQ: ABCL) shareholders back directors, auditor and Say-on-Pay - Stock Titan
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - MSN
AbCellera (ABCL) director Sandor Victor reports initial insider status on Form 3 - Stock Titan
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet - MSN
AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell (NASDAQ:ABCL) - Seeking Alpha
Q3 2025 Abcellera Biologics Inc Earnings Call Transcript - GuruFocus
AbCellera Biologics Hits Day Low of $5.50 Amid Price Pressure - Markets Mojo
AbCellera Appoints Dr. Victor Sandor to its Board of Directors - BioSpace
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Progress And Strong Q1 Results - Yahoo Finance
AbCellera’s Shift To Proprietary Drugs Puts ABCL635 And Governance In Focus - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
AbCellera appoints Victor Sandor to board of directors - Investing.com UK
AbCellera appoints Victor Sandor to board of directors By Investing.com - Investing.com South Africa
AbCellera Biologics bets on hot flash antibody as pipeline pivot gains steam - MSN
AbCellera Biologics Adds Victor Sandor to Board - TipRanks
AbCellera appoints Victor Sandor to its Board - TradingView
AbCellera (NASDAQ: ABCL) appoints oncology leader Dr. Victor Sandor as independent director - Stock Titan
Abcellera Biologics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Q1 2026 Abcellera Biologics Inc Earnings Call Transcript - GuruFocus
Abcellera Biologics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam - TradingView
ABCL Stock Jumps As Earnings Beat And Drug Data Fuel Momentum - StocksToTrade
ABCL: Lead antibody for menopausal hot flashes advances to phase II, targeting a $6B market - TradingView
AbCellera (NASDAQ: ABCL) CFO exercises 250,000 share options - Stock Titan
Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model? - simplywall.st
Abcellera Biologics stock hits 52-week high at 6.52 USD By Investing.com - Investing.com Nigeria
AbCellera Biologics Hits Day High with 12.47% Surge in Stock Price - Markets Mojo
AbCellera Biologics Hits Day High with 7.68% Surge in Stock Price - Markets Mojo
AbCellera Biologics Hits New 52-Week High of $6.79, Up 84% - Markets Mojo
After golden cross, AbCellera Biologics Inc. (ABCL)'s technical outlook is bright - MSN
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year? - MSN
Abcellera Biologics stock hits 52-week high at 6.52 USD - Investing.com
AbCellera Biologics (NASDAQ:ABCL) Is In A Good Position To Deliver On Growth Plans - Moomoo
After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright - Yahoo Finance
ABCL Technical Analysis & Stock Price Forecast - Intellectia AI
Does AbCellera (ABCL) Have a Clear Path From ABCL635 Data to a Durable Business Model? - Yahoo Finance
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):